Rj. Weaver et al., HYDROXYLATION OF THE ANTIMALARIAL DRUG 58C80 BY CYP2C9 IN HUMAN LIVER-MICROSOMES - COMPARISON WITH MEPHENYTOIN AND TOLBUTAMIDE HYDROXYLATIONS, Biochemical pharmacology, 49(7), 1995, pp. 997-1004
58C80 4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone] is an experim
ental naphthoquinone antimalarial drug which undergoes extensive alkyl
hydroxylation to a single t-butylhydroxy metabolite in man in vivo an
d also in human liver microsomes, where this is catalysed primarily by
a 54 kDa CYP2C9 form of cytochrome P450, P450hB(20-27). Microsomal 58
C80 hydroxylation (58OH) activity showed a marked inter-individual var
iation in a bank of 39 individual human livers but did not correlate w
ith the immunoquantified levels of either of two microsomal proteins (
54 and 50 kDa, respectively) recognised by a polyclonal antibody again
st CYP2C9 (P450hB(20-27)). Neither 58OH activity nor the concentration
s of the CYP2C9-immunorelated proteins showed any relationship with th
e individuals' age, sex, cigarette smoking habit, alcohol consumption
or clinical drug treatment, including long term antiepileptic therapy
with phenobarbitone or phenytoin. 58OH activity did not correlate with
either TBOH (tolbutamide hydroxylation) or MPOH (S-mephenytoin 4'-hyd
roxylation) activities, while 58C80 inhibited both TBOH and MPOH in hu
man liver microsomes non-competitively (K-i = 30 and 175 mu M for TBOH
and MPOH, respectively). 58C80 could be a useful model substrate for
measuring human CYP2C activity in vitro.